These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
101 related articles for article (PubMed ID: 1908389)
1. Effect of chronic ritanserin or clorgyline on amine and metabolite levels in rat frontal cortex. Twist EC; Mitchell SN; Corn TH; Campbell IC Eur J Pharmacol; 1991 Apr; 196(2):157-60. PubMed ID: 1908389 [TBL] [Abstract][Full Text] [Related]
2. The effect of chronic ritanserin and clorgyline administration on 5-HT2 receptor linked inositol phospholipid hydrolysis. Twist EC; Brammer MJ; Stephenson JD; Corn TH; Campbell IC Biochem Pharmacol; 1990 Nov; 40(9):2111-6. PubMed ID: 2122900 [TBL] [Abstract][Full Text] [Related]
3. 5HT2 receptor changes in rat cortex and platelets following chronic ritanserin and clorgyline administration. Twist EC; Mitchell S; Brazell C; Stahl SM; Campbell IC Biochem Pharmacol; 1990 Jan; 39(1):161-6. PubMed ID: 1688704 [TBL] [Abstract][Full Text] [Related]
4. Brain dialysis: in vivo metabolism of dopamine and serotonin by monoamine oxidase A but not B in the striatum of unrestrained rats. Kato T; Dong B; Ishii K; Kinemuchi H J Neurochem; 1986 Apr; 46(4):1277-82. PubMed ID: 2419508 [TBL] [Abstract][Full Text] [Related]
5. Chronic 5-HT2 receptor antagonist treatment alters 5-HT1A autoregulatory control of 5-HT release in rat brain in vivo. Kidd EJ; Leysen JE; Marsden CA J Neurosci Methods; 1990 Sep; 34(1-3):91-8. PubMed ID: 1701842 [TBL] [Abstract][Full Text] [Related]
6. Ethanol concentration induces production of 3,4-dihydroxyphenylacetic acid and homovanillic acid in mouse brain through activation of monoamine oxidase pathway. Jamal M; Ito A; Miki T; Suzuki S; Ohta KI; Kinoshita H Neurosci Lett; 2022 Jun; 782():136689. PubMed ID: 35598694 [TBL] [Abstract][Full Text] [Related]
7. Effect of acute administration of the 5-HT1A receptor ligand, lesopitron, on rat cortical 5-HT and dopamine turnover. Ballarín M; Carceller A; Guitart X Br J Pharmacol; 1994 Oct; 113(2):425-30. PubMed ID: 7530571 [TBL] [Abstract][Full Text] [Related]
8. Effects of CGP 11305 A, a new reversible and selective inhibitor of MAO A, on biogenic amine levels and metabolism in the rat brain. Waldmeier PC; Baumann PA Naunyn Schmiedebergs Arch Pharmacol; 1983 Sep; 324(1):20-6. PubMed ID: 6195533 [TBL] [Abstract][Full Text] [Related]
9. Role of type A and B monoamine oxidase on the formation of 3,4-dihydroxyphenylacetic acid (DOPAC) in tissues from the brain of the rat. Garrett MC; Soares-da-Silva P Neuropharmacology; 1990 Oct; 29(10):875-9. PubMed ID: 2123970 [TBL] [Abstract][Full Text] [Related]
10. Down-regulation of tryptamine receptors following chronic administration of clorgyline. Martin LL; Neale RF; Wood PL Brain Res; 1987 Sep; 419(1-2):239-43. PubMed ID: 3676728 [TBL] [Abstract][Full Text] [Related]
11. Reversibility of the interaction of CGP 11305 A with MAO A in vivo. Waldmeier PC; Feldtrauer JJ; Stoecklin K; Paul E Eur J Pharmacol; 1983 Oct; 94(1-2):101-8. PubMed ID: 6197309 [TBL] [Abstract][Full Text] [Related]
12. Differential effects of clorgyline on catecholamine and indoleamine metabolites in the cerebrospinal fluid of rhesus monkeys. Garrick NA; Scheinin M; Chang WH; Linnoila M; Murphy DL Biochem Pharmacol; 1984 May; 33(9):1423-7. PubMed ID: 6203542 [TBL] [Abstract][Full Text] [Related]
13. Potentiation of 3,4-methylenedioxymethamphetamine-induced 5-HT release in the rat substantia nigra by clorgyline, a monoamine oxidase A inhibitor. Hewton R; Salem A; Irvine RJ Clin Exp Pharmacol Physiol; 2007 Oct; 34(10):1051-7. PubMed ID: 17714093 [TBL] [Abstract][Full Text] [Related]
14. Increased total activity in the rat after L-tryptophan plus the monoamine oxidase-A inhibitor amiflamine but not after L-tryptophan plus clorgyline. Archer T; Fowler CJ; Fredriksson A; Lewander T; Magnusson O; Mohringe B; Söderberg U Br J Pharmacol; 1985 Jul; 85(3):581-90. PubMed ID: 2411326 [TBL] [Abstract][Full Text] [Related]
16. Down regulation of serotonin-S2 receptor sites in rat brain by chronic treatment with the serotonin-S2 antagonists: ritanserin and setoperone. Leysen JE; Van Gompel P; Gommeren W; Woestenborghs R; Janssen PA Psychopharmacology (Berl); 1986; 88(4):434-44. PubMed ID: 3010361 [TBL] [Abstract][Full Text] [Related]
17. Chronic effects of clomipramine and clorgyline on regional levels of brain amines and acid metabolites in rats. Mousseau DD; Greenshaw AJ J Neural Transm; 1989; 75(1):73-9. PubMed ID: 2465373 [TBL] [Abstract][Full Text] [Related]
18. Chronic treatment with the monoamine oxidase inhibitors clorgyline and pargyline down-regulates non-adrenoceptor [3H]-idazoxan binding sites in the rat brain. Olmos G; Gabilondo AM; Miralles A; Escriba PV; García-Sevilla JA Br J Pharmacol; 1993 Mar; 108(3):597-603. PubMed ID: 8385528 [TBL] [Abstract][Full Text] [Related]
19. Release of endogenous dopamine from rat isolated striatum: effect of clorgyline and (-)-deprenyl. Hársing LG; Vizi ES Br J Pharmacol; 1984 Nov; 83(3):741-9. PubMed ID: 6439273 [TBL] [Abstract][Full Text] [Related]
20. Receptor-binding properties in vitro and in vivo of ritanserin: A very potent and long acting serotonin-S2 antagonist. Leysen JE; Gommeren W; Van Gompel P; Wynants J; Janssen PF; Laduron PM Mol Pharmacol; 1985 Jun; 27(6):600-11. PubMed ID: 2860558 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]